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Abstract 
To assure the safety and the efficacy of a medicinal product, quality and batch-to-batch 
reproducibility need to be guaranteed. In case of parenteral long-acting products, the EU and US 
Authorities provide different indications, from the classification to the in vitro release assays. 
Despite their relevance, there are few in vitro experimental set-up enabling to discriminate among 
products with different in vivo behaviour. Consequently, most copies are authorised through hybrid 
applications, instead of generic ones. 
The present work reviews the actual regulatory frameworks to evaluate the in vitro release tests of 
polymer-based long-acting parenteral aiming to outline the direction followed by the Regulatory 
Agencies. 
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Introduction 
The therapeutic value of several pharmacological treatments is strictly related to the maintenance 
of a consistent plasmatic concentration for prolonged periods of time. This goal can be reached by 
developing prolonged release dosage forms, abolishing the need of frequent dosing often 
associated with toxicity issues. In case of parenteral administration, long-acting implantable or 
injectable dosage forms (LAI) are chosen to assure constant blood concentration of a potent active 
pharmaceutical ingredient (API) over months, or even years [1, 2, 3]. A wide variety of technologies 
have been proposed to control drug release, e.g. crystal suspensions [4], emulsions, liposomes, 
implantable or injectable dosage forms based on not-biodegradable and biodegradable polymers or 
in situ gelling systems.  
All of them are actually being spotlighted by global pharmaceutical companies since they can 
optimize the biopharmaceutical performance or support the repurposing of established active 
ingredients and blockbusters after expiration of the exclusivity period. Among the available 
technologies, polymer-based LAI, which are of particular interest and complexity due to the 
challenges in the product design, are considered as complex parenteral formulations requiring 
dedicated regulations to assure their quality, safety and efficacy [5, 6]. The development of 
therapeutically equivalent copies necessitates taking into account that the pharmacokinetics of a 
LAI depends not only on the physicochemical properties of the excipients, but also on the 
manufacturing process. Here, the key parameters to be considered before moving towards a LAI 
concern i) the target quality attributes of the dosage form [7], ii) the influence of the critical process 
parameters in manufacturing, iii) the interactions between the LAI and the physiological condition 
at the site of administration and iv) the PKPD of the API.  
Even if the regulatory pathway provides specific product guidelines aimed at proving the 
bioequivalence between the originator and the copy of a complex medicinal product, the 
identification of the critical attributes and the establishment of in vitro/in vivo correlations (IVIVC) 
are very complicated, due to the complex release characteristics and the lack of standardized, 
compendial in vitro release testing methods. For instance, the burst release observed under in vitro 
conditions can be masked by the in vivo absorption phase at the intramuscular site [8], or lowered 
by the formation of a fibrous encapsulation through the host immune response [9, 10, 11, 12] or 
steric hindrance by the extracellular matrix. Thus, in vitro tests might have a limited ability to 
properly predict the in vivo behaviour of formulations with significant variations in the release 
profile.  
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This review deals with the regulatory pathway to evaluate the quality of polymer-based LAI with a 
particular focus on the development of copies. As per the quality assessment required by the EMA 
and FDA, the potential applications of the in vitro testing methods to discriminate the properties of 
a LAI and, possibly, to predict the in vivo response is analysed also for waiver purposes. The 
knowledge and experience gained through decades of use of poly(lactic-co-glycolic acid) (PLGA) 
and/or poly(lactic acid) (PLA), allowed us to highline various critical factors which may be considered 
particularly prior to moving towards the development of copies of polymer based LAI. 
To better understand the issues of quality testing, the technological aspects of polymer-based LAI 
available on the market are briefly discussed in the light of their definition according to the main 
Pharmacopoeias which consider different attributes in the classification. As a consequence, the 
requirements can be different according to the applied monograph.  
Target product profile of long-acting products and technologies available on the market 
As other parenteral dosage forms, LAI are required to be sterile, biocompatible and non-
immunogenic (Figure 1). These characteristics are critical for LAI because they should remain at the 
injection/implantation site for weeks, months or years without being extruded outside or moving 
towards other tissues or inducing local adverse effects. From a biopharmaceutical point of view, the 
composition and design of LAI should assure the extended release of an API for a time period 
suitable to guarantee the therapeutic relevant concentration in the blood or locally in a specific 
tissue/organ (e.g., eye, or intra-articular cavity) for weeks, months or years. Moreover, the device 
required for injection and/or implantation should be optimized along with the implantation 
procedure. 
Moreover, LAI should also be easily removed from the administration site at the end of the release 
period or in case of harmful events. To avoid tissue damages after the extraction procedure 
biodegradable polymers (e.g. PLA and PLGA) subject to complete degradation in biocompatible 
byproducts, are generally used. Based on all target product profiles listed in Figure 1, the majority 
of polymer-based LAI are diffusion/erosion-controlled systems (e.g., microspheres or implants) 
depending on the feature of the material forming matrix [13]. Microparticles (or microspheres) are 
sphere-shaped matrices sizing from 20 to 100 μm in which the API is dispersed throughout [14]. 
They are injected by intramuscular or subcutaneous routes to obtain a systemic effect, or inserted 
in a specific site of the body (e.g., sinus, Sinuva®; eye, Ozurdex®; bones, InductOs®; intra-articular 
cavity, Zilretta®) to localize the drug release and/or to limit the systemic concentration [14, 15]. 
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Implants designed as diffusion-controlled systems consist of non-biodegradable cylinders capped at 
both ends by poly(vinyl alcohol) [PVA] or silicon, which governs the drug release. Examples of 
polymers used to this purpose are ethyl vinyl alcohol (e.g., Nexplanon®, Retisert®) and polyimide 
(e.g., Iluvien®). 
Alternatively, in situ gel systems consist in solution of an API and PLGA in N-methyl pyrrolidone 
administered subcutaneously.  Upon injection a sustained release depot (e.g., Atridox®, Eligard®) is 
formed because the solvent diffusion in the surrounding extra-cellular matrix causes the 
precipitation of the polymer entrapping the API [16]. 
Definition of LAI in the main Pharmacopoeias 
A comparison of the three main Pharmacopoeias shows that LAI classification and monographs are 
not harmonized. In the European Pharmacopoeia (Ph. Eur.) “parenteral preparations” are divided 
in two categories depending on the physical state of the dosage form, namely “Implants” and “Gels 
for injections” [17]. Because no specific information on the size and shape of “Implants” are 
reported, all implantable dosage forms are included (Figure 2).  
According to the Japanese Pharmacopeia (JP) LAI are listed among “Preparations for injection” and 
their classification is primarily based on the administration process [18]. “Implant/pellets” are solid 
or gel-like form injections administered subcutaneously or intramuscularly by a specific device or 
chirurgical procedure. Biodegradable microspheres which are resuspended before administration, 
are considered among “Prolonged release injections” generally prepared by dissolving or 
suspending active substance(s) in a non-aqueous vehicle, such as vegetable oil.  
The United States Pharmacopoeia (USP) includes LAI in two different monographs, namely 
“Suspension” and “Implant”. The former includes both in situ gelling systems and biodegradable 
microspheres administered as aqueous suspension by injection using a conventional syringe and 
needle (Figure 2). “Implant” refers to single-shaped mass made of bioabsorbable or non-
bioabsorbable polymers administered by means of a suitable special injector or procedure. Typical 
duration of these long-acting dosage forms is 2 and 3 months for bioabsorbable and up to 3 years 
for non-bioabsorbable implants. “Implant” is a comprehensive term including also “pellets” and 
“drug substance-eluting stents” [19]. However, the criticality of drug-eluting stents, which are 
medical devices in consideration of the prevalent mechanical effect, fall outside the scope of this 
review despite the release rate of the ancillary API has to be controlled [20].  
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Regarding the compendial assays, the Ph. Eur. general monograph on “Parenteral preparation” only 
specifies that sterility and particulate contamination should be evaluated for implants, and an 
appropriate test to properly demonstrate the release of the active substances should be performed 
[17]. 
In the USP monograph “<1> Injections and implanted drug products (parenterals) – product quality 
tests” [19], both general and class-specific quality tests are provided The first part includes 
“universal tests” for all parenterals related to identification assays, API impurities, particulate 
matter, sterility, bacterial endotoxins, container content, packaging systems, container-closure 
integrity and labelling. The uniformity of dosage units is required for all types of LAI, whereas the 
water content should be determined for freeze-dried products (i.e., microspheres).  
The JP specifies that “Implants/Pellets” meet the requirements of Uniformity of Dosage Units, but 
tests of foreign insoluble matter and extractable volume are enlisted in the general chapter “Tests 
for preparations”. 
Considerations on the drug release evaluation in the EU and US 
As with most dosage forms, an in vitro drug release test provides the fundamental information 
required to assess the product quality and, therefore, to support the batch release. Moreover, due 
to the expense, time, labor, and need for human subjects and/or animals to test in vitro 
performance, in vitro release is also gaining attention as a surrogate for product performance.  
In both cases, the definition of a suitable protocol is critical for a LAI. Among the reasons, is the 
duration of drug release being 30-90 days or even longer. Hence, many efforts also focused on 
shortening the time span of in vitro release experiments, to provide a quick and reliable method for 
assessing and predicting drug release. The variation of different parameters (i.e. temperature, 
solvent, ionic strength, pH, enzymes, surfactant and agitation rate) and apparatus (i.e. sample-and-
separate methods, continuous flow cell methods and dialysis methods [21]) were proposed to 
determine in vitro release profile in reasonable experimental time [21, 22].  
Beside these differences, the proper methodological approach should be carefully selected 
according to the mechanism of release. As an example, it is well-recognized that diffusion and 
erosion/degradation processes control the drug release from PLGA-based LAI. Indeed, the water 
diffusion into the PLGA matrix allows the API solubilization and its diffusion outside the system. 
Concomitantly, when the water activity causes the hydrolysis of ester bonds of the PLGA and the 
degradation products reach a molecular weight lower than about 1 KDa, the matrix starts to erode. 
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Both phenomena are influenced by the polymer molecular weight, the ratio between monomers 
and the presence of an end-capping group [23, 24]. Being prone to acid- and base-catalysed 
degradation [25], in vitro experimental parameters should be carefully defined because 
(un)expected changes may also alter the release mechanism and/or polymer degradation. For 
example, the release mechanism of triamcinolone acetonide and risperidone from PLGA 
microparticles was significantly influenced by pH [26] and temperature and apparatus [27], 
respectively. 
Regarding the compendial test, there are very few regulatory standards for LAI. Only the USP and 
BP monographs on goserelin implants recommend an in vitro method to test the drug release from 
the two commercially available dosages at 3.6 mg and 10.8 mg [28, 2928] (Table 1). For a LAI that 
does not have a dissolution test method in the USP, the FDA prepared a databased enlisting 
recommended in vitro methods to aid of developing generic drug products (Table 1). In another 
words, the reported protocols allowed to rationalize the comparison of in vitro performances 
between drug products. 
In the EU, the lack of specific and harmonized protocols leaves room for different interpretations 
and the EMA evaluates the appropriateness of the chosen method during the assessment of the 
marketing authorization application. However, the availability of harmonized dissolution protocols 
could accelerate the development of new and generic products, other than post-marketing 
variations because the comparison between products would be facilitate. 
As already mentioned, in vitro release studies can also be designed to establish an in-vitro-in-vivo 
correlation (IVIVC), namely “a predictive mathematical model describing the relationship between 
an in vitro property of a dosage form and a relevant in vivo response” [30]. Generally, IVIVC can be 
categorized into five different levels: Levels A, B, C, D, and multiple Level C [31]. If a point-to-point 
relationship between in vitro and in vivo data (i.e. Level A IVIVC) is established and validated, the in 
vitro release method can be used as a surrogate for bioequivalence studies during approval and 
when post-approval changes are required (e.g. formulation composition, as well as manufacturing 
process, equipment and site) [11, 32, 33]. The applicant can introduce post-approval changes in all 
the parts of the authorized version of CTD. Both the EMA and the FDA established multiple-level 
classification for post-approval changes based on their major/minor impact on the drug product 
benefit/risk balance [34, 35]. As a general rule, if the dosage form is particularly critical or the 
variation may influence the clinical pattern, changes are classified as major by both the Agencies. In 
the case of LAI, the EMA classifies as Type II variation changes in the (i) concentration of a single 
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dose parenteral product where the strength remains the same or (ii) coating if it is critical for the 
release mechanism [36]. Also the FDA considers “major variations” in the manufacturing process of 
implants or microparticles when they can impact on the quality, safety and efficacy of the medicinal 
product [34, 37]. Emblematic cases are the risperidone- or naltrexone-loaded microparticles since 
modifications in the manufacturing process affect significantly the feature of microspheres [37] and 
the API bioavailability [38, 39].  
Since no regulatory IVIVC guidance is available for complex non-oral drug products, the same 
principles of developing IVIVC for extended release oral dosage forms have been applied. It is a 
complicated process, due not only to the complex characteristics of LAI (e.g. multi-phasic release), 
but also to the lack of suitable in vitro release testing methods. Authors considered variables 
accounting for the methodology (i.e. apparatus [40]) and for the physiological (or physio-pathologic) 
environment, such as body temperature, vascularity, pH, buffer capacity, osmolarity, volumes or 
any tissue responses [2, 41, 42, 43]. Bio-relevant in vitro protocols should not alter the mechanism(s) 
of in vivo drug release and are applicable only when the drug release (dissolution) is the rate-limiting 
step for its absorption [44]. On the other hand, it is a hard task to simulate the conditions occurring 
in the biological environment or to identify which variables are significant [2] and the Level A IVIVC, 
demonstrated only for a few LAI [38, 39], cannot be generalized.  
How to reach the market: the regulatory approval pathways in the EU and US 
Considering the current clinical landscape, technologies for LAI production can be also applied to 
re-formulate “old drug substances” into new pharmaceutical dosage forms or formulations, 
generally with the same indication(s), but a different efficacy/safety profile, due to the modification 
of drug pharmacokinetics. Sometimes this strategy would also favour the repositioning (or 
repurposing) of a drug as a new medicinal product. In both scenarios, the applicant will submit a 
standard document of common elements (Common Technical Document, CTD), demonstrating of 
quality, safety and efficacy profiles of the product, but the supporting data required by a Regulatory 
Agency will vary according to the application type. 
Therapeutically equivalent copies 
In case of a LAI containing an already-authorized API for the same or similar therapeutic indications 
and if both the pharmaceutical form and strength are the same, the marketing authorization relies 
upon the demonstration of therapeutic equivalence with respect to the originator. If it is 
  9 
demonstrated by bioequivalence studies, a simplified dossier can be submitted to the FDA, EMA or 
a national Regulatory Agency.  
Since patent protection of LAI has generally expired, copies allow to reduce costs sustained by 
patients and healthcare systems. In the case of LAI, a 10-year period of data exclusivity is granted 
after marketing authorisation. Afterwards, even if the formulation is still protected by a patent, the 
application for marketing authorisation for a generic product based on a different technology can 
be submitted. As an example, risperidone has been approved as biodegradable microspheres 
(Risperidal® Consta®) and in-situ gelling system (Perseris Kit®) in both cases using PLGA as 
controlling release polymer. 
In the US, the procedure to be followed is the Abbreviated New Drug Application (ANDA), while in 
EU a generic application should be submitted through a centralized, decentralized or mutual 
recognition procedure. In both cases, the application does generally not requires preclinical and 
clinical data to establish safety and efficacy. Instead, the applicant must scientifically demonstrate 
that the therapeutics performance of the generic and innovator are equivalent. Therefore, chemical, 
pharmaceutical and biological documentation provided by Module 3 is the most critical, as the 
formulation design plays a crucial role in controlling release technologies. Both in the EU and the 
US, products can be considered therapeutically equivalent only if they have identical active 
ingredient(s), dosage form, strength, route of administration and they are bioequivalent to the 
reference product [45, 46]. In case of parenteral administration, the regulatory approvals can be 
made through a waiver for “exception excipient regulations,” which covers preservatives, buffers, 
and antioxidants used in parenteral drug products. As an example, a biowaiver can be generally 
accepted for generics of injectable aqueous solution.  
For all other inactive ingredients, namely those interacting with the API or influencing its 
biodistribution, However, two different situations are envisaged by the two main Regulatory 
Agencies. The EMA still considers biowaivers if the test and the reference products contain the 
same excipients in very similar quantity and proper justifications are provided to demonstrate that 
the pharmacokinetics is not affected [47]. Conversely, FDA states that the regulatory pathway of 
an ANDA can be submitted to the FDA only if the copy contains contain the same inactive 
ingredients (Q1) and in the same concentration (Q2) as the reference listed drug [48]. But LAI are 
considered as complex dosage forms [49], and therefore, they must fulfil the Q1/Q2 sameness 
requirement [50]. As an example, the controlled correspondence to request a Q1/Q2 evaluation of 
proposed formulations based on PLGA and/or PLGA regards the polymer composition (ratio 
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between glycolic and lactic acids), molecular weight, weight distribution and polymer architecture 
(e.g., linear or star-branched) [51]. The application of these standards makes the pathway towards 
the marketing authorization of a generic LAI more difficult in the US than in the EU. To the best of 
our knowledge, LAI copies are authorized and marketed in several EU countries, but none of them 
have been either authorised by ANDA procedure or classified as bioequivalent in the FDA Orange 
book.  One of the possible explanations of this difference is the difficulties in demonstrating the 
Q1/Q2 sameness requirement for all inactive ingredients because the exact qualitative and 
quantitative composition of excipients may not be known or available at the moment of the drug 
product development. To solve this problem, a rigorous approach of reverse engineering can be 
proposed to describe product attributes useful to develop generic leuprolide-PLGA microspheres, 
as recently proposed on 1-month Lupron-Depot® [7]. 
Even so, criticality of materials, product design and manufacturing method may lead to differences 
in the biopharmaceutical properties and bioavailability [52, 53]. As an example, compositionally 
equivalent PLGA microparticles loaded by risperidone with manufacturing differences , presented 
distinctly different physicochemical properties which were also confirmed by PK data in rabbits 
[38].  
 
Moreover, the lack of compendial in vitro release testing and validated IVIVC may limit the use of 
waivers in the marketing authorisation of LAI copies. The applicants can refer to the FDA database 
of dissolution methods (Table 1) or product-specific bioequivalence guidance (Table 2) which 
depicts three scenarios:  
i. bioequivalence studies should be performed for all strengths available;  
ii. bioequivalence studies should be performed for some strengths, but waivers can be 
accepted for other strengths available (a linear relationship between the strength and the 
pharmacokinetic data are needed); 
iii. both bioequivalence studies and in vitro release studies should be performed to support the 
equivalence between test and reference products (e.g., risperidone).  
The EMA issued only a bioequivalence guideline on octreotide acetate depot powder (Table 2) [54] 
at the highest strength (i.e., 30 mg) without providing details on the study design for lower strengths 
(i.e., 10 mg, 20 mg). 
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However, therapeutically equivalent copies of a LAI cannot be authorized following the procedure 
used for generics when:  
a) the test product does not fulfil the Q1/Q2 sameness requirement or the generic definition in the 
US and UE, respectively (e.g., changes in active substance, strength, pharmaceutical form);  
b) bioequivalence cannot be considered as a surrogate of the therapeutic equivalence (e.g., locally-
applied and locally-acting drug products);  
c) the route of administration is changed with respect to the reference product, but a therapeutic 
improvement is not expected.  
In these conditions, the hybrid application includes preclinical and clinical data to demonstrate the 
therapeutically equivalence of test and the reference product. The body of data included in the 
comparability studies varies case-by-case according to the complexity of the drug product or the 
therapeutic indications.  
Therapeutic improvement and repurposing of old drug substances 
An “old” API, even if no longer on the market, can be re-formulated in order to improve its 
benefit/risk balance for the same/similar therapeutic indication or totally new ones. Leuprolide 
acetate is one of the most well-known examples: short-term use of GnRH agonists stimulates 
pituitary gonadotropin release, while long-term administration leads to inhibition of the pituitary-
gonadal axis due to downregulation of the GnRH pituitary receptors. Hence, the switching from the 
“one-shot” subcutaneous injection of the conventional parenteral solution to biodegradable 
microspheres allowed to obtain a therapy to treat a variety of endocrine disorders that are 
responsive to reductions in gonadal steroids [55].  
In case of repurposing, the data required by the Regulatory Agency can be reduced since the API 
has already been authorized for the same or similar therapeutic indications. Indeed, even if a 
therapeutic improvement is expected, the efficacy and safety may be partially derived from 
literature data or provided by medicinal products already on the market even if in a different 
pharmaceutical form. Consequently, the information required will vary, based on the complexity of 
the benefit/risk balance assessment and on the differences (or similarities) with a reference 
medicinal product already authorized. However, detailed information is required on substances, 
both the API and the excipients, on pharmaceutical development and on in vitro and in vivo 
biopharmaceutical performances [56]. The critical quality attributes of the product should be also 
identified and studied as a function of its intended use and route of administration.  
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In the US, a repurposed drug is not eligible for an Abbreviated New Drug Application (ANDA), but 
the applicant can follow the 505(b)(2) New Drug Application (NDA) which allows the use of non-
proprietary studies that have previously achieved a high standard of quality and safety to support 
any part of an application [57].  
On the contrary, in the EU this condition falls in the “hybrid” procedure described by Article 10(3) 
of Directive 2001/83/EC. In this situation, the application relies, in part, upon the dossier of a 
reference medicinal product and the results of appropriate own non-clinical and/or clinical studies. 
As an example, EMA recently approved a buprenorphine-loaded implant for the substitution 
treatment of opioid dependence in clinically stable adult patients [58], based on a dossier that 
contain reduced less preclinical data, since the pharmacodynamic of buprenorphine is well-known 
and the clinical data included the comparison between the clinical and pharmacokinetic 
performance of the implant and the existing authorized medicinal product (i.e. sublingual tablets).  
However, repurposing is not just a matter to find a new use for an “old” API: to support a new 
indication, the regulatory approval requires a detailed research and development process. Indeed, 
the different pharmacokinetics and the pharmacodynamics with respect to the reference product, 
can change the benefit/risk balance. Even if a hybrid application is still feasible, the safety and 
efficacy of a repurposed API may not be extrapolated, or supplemented, from data available in the 
public domain, but supporting studies should be required. Therefore, the amount of clinical data to 
be provided may be so huge to make the preparation of a complete dossier necessary.  
As mentioned, comparative in vitro (e.g., release studies) or in vivo studies (e.g., bioequivalence) 
may be also performed to compare the performances of formulation(s) used in clinical studies to 
those of commercial formulation(s) or to support changes of formulation or its manufacturing 
process in the late stage of pharmaceutical development. In this context, only Level A IVIVC are 
relevant from a regulatory point of view for wavering bioequivalence studies [59, 60].  
In case of old API repurposed as new formulations, clinical studies are required to characterize the 
in vivo performance. For example, the EMA requires pharmacokinetic studies aimed at evaluating 
the drug diffusion from the implantation site, which is the rate-limiting steps determining the 
systemic availability and the risks of dose-dumping [60]. In particular, the single-dose or multiple-
dose studies are focused on clinical aspects, e.g. the site-dependent absorption pattern, the 
fluctuation in drug concentration and lag-times. When more than one strength is considered, the 
possible proportionality in absorption profile should be investigated. Moreover, the applicant 
should perform at least single-dose and multi-dose studies to compare in vivo performances after 
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intramuscular and subcutaneous administration with respect to an authorized reference [60]. The 
multi-dose study is needed unless the bioavailability after the single-dose (expressed as AUC0-t) is 
higher than 90% of the global bioavailability (expressed as AUC0-∞) in both test and reference. The 
investigations should be performed using only one strength, only if the others are proportional in 
composition, exhibit a similar in vitro profile and there is a linear correlation between the strength 
and the pharmacokinetic profile.  
Conclusions 
The variety and complexity of the technologies used to produce LAI which are designed to meet 
specific medical needs, dictate an assessment of in vitro testing on a case-by-case basis. To speed-
up their development, more product-dedicated guidelines or in vitro compendial tests should be 
elaborated to support formulation, testing and approval. By increasing our understanding, the 
number of copies of LAI on the market could also increase. In any case, the lack of standardized in 
vitro methods shall limit the market entry of copies of a LAI, but “in-house” methods should be 
accepted when and whether are able to predict the biopharmaceutical behaviour.  
There are at least two other challenges to the development generic products. First the US and the 
EU requirements are substantially different: the FDA considers sameness of specific components, 
namely identity and quantity, as the reference listed drug; in the EU a simplified procedure can be 
followed when relevant analytical methods are established and the characteristic properties of 
active and inactive ingredients are well-known. Next, in the EU issues related to those products 
approved before the introduction of the centralized procedure need to be addressed since the 
approval through applications to single European Member States determined the lack or, at least, 
the impossibility to find public information on the in vitro characterization of marketed products. 
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Table 1 – Protocols for release tests included in a Pharmacopeia monograph or accepted by Regulatory Agencies. 
ERS: extended release suspension; ID: Injectable Depot; IM: Intramuscular suspension/injection; IMT: Implant; MP: microparticles; NA: not available; PBS: phosphate buffer solution; PQR: product 
quality review. 
  
Drug product Dose Apparatus Sample Medium Volume Temp. Stirring Sampling time 
Dexamethasone IMT 
(FDA [61]) 
NA 
USP VII (with 
reciprocating 50 
mesh baskets 
NA PBS + 0.05 g/L SDS 30 mL 45 °C 30 cycles/min 
12, 24, 48, 72, 96, 120, 144, 168, 
192, 216, 240 h 
Goserelin implant 
(USP [28] BP [29]) 
3.6 mg/ 
10.8 mg 
Flat-bottomed, 
borosilicate glass 
jar (120 mL) with a 
tight plastic cap 
1/5 unit 
(3.6/10.8 mg) 
pH 7.4 phosphate/ 
citrate buffer 
50 mL 39 °C NA 
7, 14, 17, 21 and 28 days (3.6mg) 
3, 14, 35, 56, 84 days (10.8 mg) 
Goserelin implant 
(FDA [61]) 
3.6 mg/ 
10.8 mg 
120 mL Wheaton 
jar 
NA pH 7.4 PBS 50 mL 39 °C 
Swirl orbit at 
205 rpm for 6 
s 
7, 14, 17, 21 and 28 days (3.6mg) 
3, 14, 35, 56, 84 days (10.8 mg) 
Leuprolide acetate 
ERS (FDA [61]) 
NA USP II or IV NA NA NA NA NA NA 
Naltrexone ERS 
(FDA [62]) 
380 mg 
250 mL HDPE 
plastic bottle 
600 mg 
pH 7.4 PBS + 0.02% 
Tween 20 + 0.02% 
sodium azide 
(osmolarity: 270 
mOsm/kg) 
200 mL 37 °C NA 1, 7, 14, 28 days 
Octreotide ERS (FDA 
[61]) 
NA USP II or IV NA NA NA NA NA NA 
Risperidone MP 
(FDA [63]) 
25 mg Cylinder bottle NA 
pH 7.4 HEPES buffer 
+ sodium azide + 
NaCl + Tween 20 
200 mL 
37 and 
45 °C 
NA 
1, 21 days (37 °C) 
Multiple time points from 0 to 8 
days (45 °C) 
Triamcinolone 
acetonide MP 
(Zilretta® PQR [64]) 
40 mg USP II 160 mg of MPs 
pH 7.2 PBS (10 mM) 
+ 0.3% SDS + 0.02% 
sodium azide 
1000 mL 35 °C 75 rpm 4, 24, 48, 120 h 
Triptorelin pamoate 
ERS 
(FDA [61]) 
NA USP II NA 
50 mL methanol to 
950 mL water 
950 mL NA 75 rpm 1, 8, 24, 96, 168 h 
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Table 2 – Guidelines issued by the EMA and FDA on long-acting parenteral products. 
ERS: extended release suspension; ID: Injectable Depot; IM: Intramuscular Injection/suspension; IMT: Implant; IS: Injectable suspension; MPs: microparticles; NA: 
not available. 
* not reported in the guideline. 
 
API Dosage 
forms 
Source Recommended study to assess 
bioequivalence 
Strengths Waiver Ref.  
Goserelin acetate  IMT FDA 2 single-dose, parallel in vivo studies 3.6, 10.8 mg --* [65] 
Leuprolide acetate  ID FDA 
2 single-dose, randomized, parallel 
in vivo studies 
30, 45 mg/vial For 11.25 and 22.5 
mg/vial (vs 30 
mg/vial) 
[66] 
Leuprolide acetate IMT FDA 
1 single-dose, parallel, crossover in 
vivo study 
Equivalent to 65 mg of 
base 
--* [67] 
Leuprolide acetate, 
Norethindrone 
acetate  
ID + oral 
tablet 
FDA 
2 single-dose, randomized, parallel 
in vivo studies 
11.25, 3.75mg/vial 
leuprolide acetate ID 
--* 
[51] 
1 steady state, crossover in vivo 
study 
5 mg Norethindrone 
acetate tablet 
Naltrexone ERS FDA 1 parallel in vivo study 380 mg/vial --* [62] 
Octreotide acetate MPs EMA 
1 single-dose, parallel design in vivo 
study 
30 mg --* [54] 
Octreotide acetate MPs FDA 
1 single-dose, parallel design in vivo 
study 
30 mg For 10, 20 mg (vs 
30 mg) 
[68] 
Risperidone MPs FDA 
1 in vitro drug release 25 mg/vial For 12.5, 37.5, 50 
mg/vial (vs 25 
mg/vial) 
[63] 
1 in vivo, two period, crossover, 
steady-state study 
12.5, 25, 37.5, 50 mg/vial 
Triptorelin 
pamoate 
IM FDA 
3 single-dose, parallel design in vivo 
with pharmacokinetics endpoints 
3.75, 11.5, 22.5 mg 
base/vial 
--* [69] 
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Figure legends: 
 
Figure 1 – Target product profile of a LAI. The mandatory attributes are reported in solid 
circles, whereas the desirable ones in dotted circles. 
 
Figure 2 – Schematic classifications of LAI according to the main Pharmacopoeia with respect 
to the standard terms proposed by EDQM. 
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